Real‐world clinical experience with NGS ‐based chimerism analyses in haematopoietic stem cell transplant patients
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20191 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jin Ju Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Korea. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, High-Throughput Nucleotide Sequencing, Transplantation Chimera, Chimerism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Next‐generation sequencing (NGS) has improved the sensitivity of chimerism assays beyond the limitations of conventional short tandem repeat (STR) methods, enabling the detection of minimal recipient haematopoiesis after haematopoietic stem cell transplantation (HSCT). We evaluated the clinical utility of CASAL, an NGS‐based chimerism assay, in routine practice. We retrospectively analysed 310 patients who underwent STR or CASAL chimerism testing between April 2021 and September 2023. CASAL provided significantly more informative markers than STR (median 18 vs. 6; p < 0.001). Among 260 CASAL samples with paired molecular minimal residual disease (MRD) data, concordance at the 10 −4 threshold was ~84%. Low‐level mixed chimerism (2%–5%) detected beyond 1 month post‐HSCT was associated with impending relapse. In survival analyses, patients with both MC and MRD positivity (MC/MRD + ) had the highest relapse risk across both platforms. Multivariable Cox regression confirmed MC/MRD + as an independent predictor of relapse (hazard ratio 5.87, 95% CI: 1.17–29.57). CASAL enables sensitive chimerism monitoring and shows a strong correlation with molecular MRD and clinical outcomes. These findings support its clinical utility for individualized post‐HSCT surveillance, especially in patients lacking leukaemia‐specific molecular targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Korea.
- Department of Laboratory Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
- Department of Laboratory Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea.
- Graduate School of Medical Science, Brain Korea 21 PLUS Project, Yonsei University College of Medicine, Seoul, Korea.
- Dxome Co. Ltd., Seongnam-si, Gyeonggi-do, Korea.
ORCID-Profile: Jin Ju Kim, Soon Sung Kwon, Saeam Shin
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J. J., Kwon, S. S., Choi, Y. J., Kang, Y., Park, Y. J., Shin, S., Lee, S. T., & Choi, J. R. (2025). Real‐world clinical experience with NGS ‐based chimerism analyses in haematopoietic stem cell transplant patients. British Journal of Haematology. https://doi.org/10.1111/bjh.20191
Vancouver
Kim JJ, Kwon SS, Choi YJ, Kang Y, Park YJ, Shin S, et al. Real‐world clinical experience with NGS ‐based chimerism analyses in haematopoietic stem cell transplant patients. British Journal of Haematology. 2025. doi:10.1111/bjh.20191
BibTeX
@article{Kim2025,
author = {Kim, Jin Ju and Kwon, Soon Sung and Choi, Yu Jeong and Kang, Yehyun and Park, Yu Jin and Shin, Saeam and Lee, Seung-Tae and Choi, Jong Rak},
title = {Real‐world clinical experience with NGS ‐based chimerism analyses in haematopoietic stem cell transplant patients},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20191}
}
EUVIMED